<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837277</url>
  </required_header>
  <id_info>
    <org_study_id>SevereHIV</org_study_id>
    <nct_id>NCT01837277</nct_id>
  </id_info>
  <brief_title>Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients</brief_title>
  <acronym>IDEA</acronym>
  <official_title>Impact of a Dolutegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Bahiana de Infectologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação Bahiana de Infectologia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current available antiretroviral (ARV) agents make possible a successful treatment of&#xD;
      virtually all HIV-infected patients, but some problems related to early mortality are still&#xD;
      of concern, mainly in resources-limited settings. There are several published reports showing&#xD;
      that such patients are at a significantly higher risk of death during the first months of&#xD;
      treatment, in comparison with the observed outcomes in developed countries. One of the&#xD;
      consistently detected risks for early mortality across these reports is the baseline low CD4&#xD;
      count, although it does not seem to be the only reason for such outcome. In Brazil and other&#xD;
      developing countries, there is still a large proportion of AIDS patients who are diagnosed&#xD;
      with AIDS, or only seek health care for HIV infection late in the course of disease.&#xD;
      Dolutegravir (DTG), the first HIV-1 integrase inhibitor, is a potent and safe ARV drug. The&#xD;
      available evidence suggest it promotes a faster decline in HIV-1 plasma viremia, and a higher&#xD;
      increase in CD4 cells count, in comparison with those in Efavirenz (EFV) arm. The&#xD;
      investigators propose to compare the impact of DTG versus EFV in the early mortality rates&#xD;
      for severely ill (CD4+ cells count &lt;50 cells/mm3) patients starting ARV therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early mortality</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Severely Immunocompromised HIV Patients</condition>
  <arm_group>
    <arm_group_label>Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Patients will receive ART regimen based on investigational drug Dolutegravir 50 mg QD + TDF 300 mg QD+ 3TC 150 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Patients who received ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year, befor the use of DTG as SOC for first-line therapy (historic controls)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50 mg</intervention_name>
    <description>Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)</description>
    <arm_group_label>Dolutegravir</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz-based regimens</intervention_name>
    <description>Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)</description>
    <arm_group_label>Efavirenz</arm_group_label>
    <other_name>Efavirenz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA&#xD;
             &gt;1,000 copies/ml)&#xD;
&#xD;
          -  No previous use of any ARV drug (drug-naïve patients)&#xD;
&#xD;
          -  Presence of clinical symptoms according to Rio de Janeiro / Caracas´ AIDS definition&#xD;
             (Asthenia, Cachexia/Wasting, Cough, Dermatitis, persistent, Diarrhea, Fever,&#xD;
             Lymphadenopathy, Candidiasis, oral, or hairy leukoplasia, Central nervous system&#xD;
             dysfunction, Herpes zoster in individual younger than 60 years of age)), and/or any&#xD;
             active AIDS-defining condition&#xD;
&#xD;
          -  Baseline CD4+ cells count equal or lower than 50 cells/mm3&#xD;
&#xD;
          -  Age equal or higher than 18 years&#xD;
&#xD;
          -  HIV-1 plasma viral load ≥ 1,000 copies of HIV-1 RNA/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undetectable plasma viral load at screening&#xD;
&#xD;
          -  CD4 cells count&gt;50 cells/mm3&#xD;
&#xD;
          -  Asymptomatic individuals&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fundação Bahiana de Infectologia/SEI</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundação Bahiana de Infectologia</investigator_affiliation>
    <investigator_full_name>Carlos Brites</investigator_full_name>
    <investigator_title>Senior Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

